Vanda Pharma shares decline as goal of itch drug study not reached
Vanda Pharmaceuticals Inc. (VNDA) shares fell in the extended session Wednesday after the biotech drug developer said a study of its treatment for a type of eczema did not reach the stated goal. Vanda shares fell 6.7% to $15.86 after hours, following a brief halt in trading. The company said a mid-stage clinical study of its drug tradipitant showed that while the drug showed improvement in itching in patients with atopic dermatitis compared with a placebo, the results were not statistically significant.
-Wallace Witkowski; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
September 13, 2017 16:49 ET (20:49 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.